Nuvation Bio Inc. filings document the regulatory record of a public oncology company with Class A common stock listed on the New York Stock Exchange. The company's 8-K disclosures cover operating and financial results, material agreements, clinical and regulatory updates for taletrectinib and safusidenib, pipeline decisions involving its drug-drug conjugate program, and other material-event disclosures.
Proxy materials describe board elections, auditor ratification, executive compensation votes, shareholder voting procedures, and governance matters. Capital-structure filings identify the company's registered securities, including Class A common stock and historical warrant-related disclosures, while Form 25 records document removal of a warrant class from exchange listing and registration.
Cui Xiangmin reported acquisition or exercise transactions in this Form 4 filing.
Nuvation Bio Inc. reported that director Xiangmin Cui received a grant of stock options covering 74,813 shares on February 27, 2026. The options have a grant price of $0.00 per share and represent a right to buy company stock rather than immediate ownership.
According to the terms, the option vests as to 1/24 of the shares on the one-month anniversary of January 1, 2026, and then monthly over the following 23 months, as long as Cui remains in continuous service on each vesting date. After this grant, Cui holds 74,813 stock options directly.
Hattersley Gary reported acquisition or exercise transactions in this Form 4 filing.
Nuvation Bio Inc. reported that its Chief Scientific Officer, Gary Hattersley, received a grant of stock options covering 748,130 shares of common stock. The options were awarded at a grant price of $0.00 per option, reflecting a non-cash compensation award rather than an open-market purchase.
According to the vesting terms, 25% of the option grant will vest on the one-year anniversary of 2/27/2026, with the remaining portion vesting in equal monthly installments over the following 36 months, subject to his continuous service on each vesting date.
Nuvation Bio Inc. reported that its Chief Technical Operations officer, David C. Hanley, received a grant of 748,130 stock options. These options were acquired as a derivative security award and increase his directly held option position to 748,130 options.
According to the terms, the option vests as to 25% on the one-year anniversary of February 27, 2026, with the remaining 75% vesting in equal monthly installments over the following 36 months, contingent on Hanley’s continuous service on each vesting date.
Hung David reported acquisition or exercise transactions in this Form 4 filing.
Nuvation Bio Inc. reported that President and CEO David Hung received a grant of stock options covering 1,995,012 shares. These options were awarded at no cash cost to him as a grant, not an open-market purchase.
According to the disclosure, the option vests 25% on the one-year anniversary of 2/27/2026, with the remaining shares vesting monthly over the following 36 months, as long as he continues in service on each vesting date.
Nuvation Bio Inc. is a clinical-stage oncology company that has transitioned into a commercial organization with the U.S. launch of IBTROZI (taletrectinib) in June 2025 for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer. IBTROZI is also approved in Japan and China through partners, supported by strong Phase 2 data showing high objective response rates and long durations of response in both TKI‑naïve and TKI‑pretreated patients. The company has structured global licensing deals with Innovent, Nippon Kayaku and Eisai that provide upfront payments, milestones and tiered royalties across major territories. Beyond taletrectinib, Nuvation is advancing safusidenib, a brain‑penetrant mutant IDH1 inhibitor, in a 300‑patient global Phase 3 SIGMA maintenance trial for high‑risk or high‑grade IDH1‑mutant astrocytoma, building on encouraging Phase 1–2 results in glioma. The company is also investing in a proprietary drug‑drug conjugate platform, relies on third‑party manufacturers, and highlights extensive patent coverage for taletrectinib and safusidenib with expected expiries into the 2030s and potential term extensions.
Nuvation Bio Inc. reported fourth-quarter and full-year 2025 results, highlighting the first commercial contributions from IBTROZI and stronger collaboration revenue. Net product revenue from U.S. sales of IBTROZI reached $15.7 million in Q4 and $24.7 million for 2025.
Total revenue rose to $41.9 million in Q4 and $62.9 million for 2025, driven by a $25 million milestone from Nippon Kayaku and higher license, service, supply and royalty revenue. The company ended 2025 with $529.2 million in cash, cash equivalents and marketable securities and reported a narrower full-year net loss of $204.6 million, or $(0.60) per share, compared with a $567.9 million loss in 2024.
Nuvation Bio Inc. has had its redeemable warrants removed from listing and registration on the New York Stock Exchange. These warrants were exercisable on a one-for-one basis for shares of Class A common stock at an exercise price of $11.50 per share.
The New York Stock Exchange filed this notification, certifying that it followed its own rules to strike this class of securities from listing and registration. The filing also states that Nuvation Bio complied with the Exchange’s rules and the requirements governing voluntary withdrawal of this warrant class from the Exchange.
Nuvation Bio Inc. entered into a License and Collaboration Agreement with Eisai Co., Ltd. covering taletrectinib in a broad Territory including Europe, parts of the Middle East, Africa, Asia-Pacific, Canada and other countries. Eisai will pay Nuvation Bio upfront consideration of €50 million, a near-term regulatory milestone of €25 million, and up to an aggregate of €120 million tied to sales milestones, plus tiered royalties in the low- to high-teens on annual net sales of licensed products.
The agreement lasts on a product-by-product basis through the applicable royalty term, after which Eisai’s license becomes non-exclusive and royalty-free for that product. Eisai and Nuvation Bio each have defined termination rights, including for material breach, certain safety issues, failure to obtain specified EU regulatory approvals by a set date, invalidation of fundamental patents in a country, or bankruptcy. Nuvation Bio also reported that it released a press release with preliminary unaudited year-end cash, cash equivalents and marketable securities and preliminary net product revenue of IBTROZI, and furnished a joint press release and an updated corporate presentation.
Nuvation Bio Inc. reported insider equity transactions by its Chief Medical Officer. On 12/01/2025, the officer exercised stock options to acquire 150,000 shares of Class A common stock at an exercise price of $2.93 per share. On the same date, the officer sold 150,000 shares of Class A common stock in an open-market transaction with a weighted-average sales price of $7.8217 per share, with individual sale prices ranging from $7.80 to $7.855.
After these transactions, the officer beneficially owned 18,000 shares of Class A common stock directly and held 165,000 stock options that remain outstanding, each option relating to Class A common stock. The option originally covered 150,000 shares, vested 25% after one year from 08/29/2022 and monthly over the following 36 months, conditioned on continued service.
A holder of Class A common stock of the issuer with symbol NUVB has filed a Form 144 indicating an intent to sell 150,000 shares through Morgan Stanley Smith Barney LLC. The planned sale has an aggregate market value of $1,173,255.00, while 342,833,433 shares of this class were outstanding.
The 150,000 shares were acquired on 12/01/2025 by exercising stock options under a registered plan, paid in cash on the same date. The filing also lists recent sales by the same seller, including 10,000 common shares on 11/26/2025 for $80,000.00 and 20,000 common shares on 11/20/2025 for $140,074.00. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer.